Detection and Characterization of *Leishmania (Leishmania)* and *Leishmania (Viannia)* by SYBR Green-Based Real-Time PCR and High Resolution Melt Analysis Targeting Kinetoplast Minicircle DNA

Marcello Ceccarelli¹, Luca Galluzzi¹*, Antonella Migliazzo², Mauro Magnani³

¹ Department of Biomolecular Sciences, University of Urbino “Carlo Bo”, Fano (PU), Italy, ²Istituto Zooprofilattico Sperimentale della Sicilia, Palermo (PA), Italy, ³Department of Biomolecular Sciences, University of Urbino “Carlo Bo”, Urbino (PU), Italy

Abstract

Leishmaniasis is a neglected disease with a broad clinical spectrum which includes asymptomatic infection. A thorough diagnosis, able to distinguish and quantify *Leishmania* parasites in a clinical sample, constitutes a key step in choosing an appropriate therapy, making an accurate prognosis and performing epidemiological studies. Several molecular techniques have been shown to be effective in the diagnosis of leishmaniasis. In particular, a number of PCR methods have been developed on various target DNA sequences including kinetoplast minicircle constant regions. The first aim of this study was to develop a SYBR green-based qPCR assay for *Leishmania (Leishmania)* infantum detection and quantification, using kinetoplast minicircle constant region as target. To this end, two assays were compared: the first used previously published primer pairs (qPCR1), whereas the second used a nested primer pairs generating a shorter PCR product (qPCR2). The second aim of this study was to evaluate the possibility to discriminate among subgenera *Leishmania (Leishmania)* and *Leishmania (Viannia)* using the qPCR2 assay followed by melting or High Resolution Melt (HRM) analysis. Both assays used in this study showed good sensitivity and specificity, and a good correlation with standard IFAT methods in 62 canine clinical samples. However, the qPCR2 assay allowed to discriminate between *Leishmania (Leishmania)* and *Leishmania (Viannia)* subgenera through melting or HRM analysis. In addition to developing assays, we investigated the number and genetic variability of kinetoplast minicircles in the *Leishmania (L.) infantum* WHO international reference strain (MHOM/TN/80/IPT1), highlighting the presence of minicircle subclasses and sequence heterogeneity. Specifically, the kinetoplast minicircle number per cell was estimated to be 26,566±1,192, while the subclass of minicircles amplifiable by qPCR2 was estimated to be 1,263±115. This heterogeneity, also observed in canine clinical samples, must be taken into account in quantitative PCR-based applications; however, it might also be used to differentiate between *Leishmania* subgenera.

Citation: Ceccarelli M, Galluzzi L, Migliazzo A, Magnani M (2014) Detection and Characterization of *Leishmania (Leishmania)* and *Leishmania (Viannia)* by SYBR Green-Based Real-Time PCR and High Resolution Melt Analysis Targeting Kinetoplast Minicircle DNA. PLoS ONE 9(2): e88845. doi:10.1371/journal.pone.0088845

Editor: Joao Inacio, National Institute for Agriculture and Veterinary Research, IP (INIAV, I.P.), Portugal

Received October 11, 2013; Accepted January 11, 2014; Published February 13, 2014

Copyright: © 2014 Ceccarelli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Funds used to support the authors throughout the study period and manuscript preparation were from Department of Biomolecular Sciences of University of Urbino. The fund had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: luca.galluzzi@univel.it

Introduction

Leishmaniasis is a neglected disease of the Old and New Worlds with a broad clinical spectrum encompassing asymptomatic infection and three main clinical syndromes: visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucosal leishmaniasis (ML). Worldwide, at least 15 *Leishmania* species are pathogenic for *Homo sapiens*. They are primarily transmitted by phlebotomine sandflies, although infection may also occur sporadically through blood transfusion, contaminated needles, and organ transplantation [1]. *Leishmania donovani* complex (including *L. infantum* and *L. donovani*) belongs to the subgenus *Leishmania* (*Leishmania*) and it is the etiological agent of VL, while the species belonging to the subgenus *Leishmania* (*Viannia*) are the etiological agents of CL and ML. The leishmaniasis is still a public health problem in 98 countries, affecting both rural and urban areas. Worldwide there are an estimated 0.2–0.4 million new cases of VL and 0.7–1.2 million new cases of CL annually, while 12 million people are currently affected by the disease [2]. The VL mortality is second only to malaria among parasitic diseases [3].

In zoonosis caused by *L. (L.) infantum*, dogs are the main reservoir for the disease and canine visceral leishmaniasis (CVL) is considered to be a major problem in veterinary medicine [4,5]. Cases of canine leishmaniasis have been reported in over 50% of the countries where human leishmaniasis is endemic, and the Mediterranean Basin is one of the most affected areas [6]. Moreover, many infected dogs are asymptomatic [7,8].

In this context, efficient and reliable diagnostic approaches in veterinary medicine are very important in the treatment of symptomatic and asymptomatic dogs. Moreover, the definition of the subgenus/complex in humans may be useful in helping physicians to choose the appropriate therapeutic protocols and in gaining insights into the disease evolution [9].

To this end, many diagnostic systems have been developed. Among the serological methods, the indirect fluorescence antibody
test (IFAT) is considered by the World Organization for Animal Health (OIE-Office International des Epizooties) as a reference serologic method [10]. Nevertheless, serological methods are not always reliable when dealing with prepatent periods, remission stages, and the appearance of non-specific cross-reactions or latent forms of the disease like in “cryptic leishmaniasis” [11]. Moreover, in endemic areas, a significant number of animals display antibody titres ranging from 1:40 to 1:80 (below the positivity threshold: titre ≥ 1:160), referred to as uncertain titres or “borderline titres” [12].

Molecular techniques can lead to improvements in the diagnosis of leishmaniasis; in particular quantitative PCR (qPCR) could play an important role in Leishmania detection and the monitoring of therapy [13,14] in humans and animals. Several PCR methods have been developed on various Leishmania target sequences. The conserved region of Leishmania kinetoplast DNA (kDNA) minicircles has been used as a specific target for conventional or quantitative PCR assays [15–17]. In fact, Leishmania belongs to the Kinetoplastida order, Trypanosomatidae family, in which all the members contain a kinetoplast situated at the base of the flagellum. The kinetoplast contains a concatenated network of circular DNA molecules [18], i.e. mitochondrial DNA, composed of minicircles and maxicircles. The minicircles, which encode for guide RNAs (gRNAs) required for editing the mRNA from maxicircles, have been reported to be present in about 10,000 copies per parasite [19,20]. Structurally, the kDNA minicircle is organized into one to four conserved regions representing approximately 10% of the molecule and an equal number of variable regions [21].

In this study, we compared two SYBR green–based qPCR assays (named qPCR1 and qPCR2), targeting the kDNA minicircle constant region, for the detection and estimation of the Leishmania parasites in canine clinical samples. Then, we evaluated the possibility to discriminate among the subgenera Leishmania (Leishmania) and Leishmania (Viannia) using a high resolution melt (HRM) approach. Moreover, the number of kDNA minicircles and their genetic variability were also investigated in an attempt to characterize the L. (L.) infantum WHO reference strain and gain insight the minicircle heterogeneity in veterinary clinical samples.

**Materials and Methods**

**Ethical Statement**

Approval of the study was obtained on July 31st 2012 from the Ethical Committee for Animal Experiments of the University of Urbino (CESA). The study’s title was “Diagnosi biomolecolare della leishmaniosi attraverso l’uso di campioni clinici non invasivi e loro utilizzo per il monitoraggio terapeutico” (Prot. CESA 2/2012).

**Leishmania DNA**

A Chelex-purified DNA from promastigotes of L. (L.) infantum MHOM/TN/80/IPT1 (WHO international reference strain), used in Italy as the national reference strain, was obtained from the Institute of Experimental Preventive Veterinary Medicine (Istituto Zooprofilattico Sperimentale) (IZS) of Sicily, the National Italian Reference Centre for leishmaniasis located in Palermo, Italy. The equivalent concentration of reference sample was 10^8 parasites/ml. DNA quantification was performed by fluorimetric analysis using the Qubit 2.0 Fluorometer (Invitrogen).

The DNA concentration was 23.5 ng/µl, and the content of DNA per cell was calculated to be 235 fg/parasite, in agreement with literature data [22,23].This value confirmed the accuracy of parasite concentration in the DNA reference sample, and supported the accuracy of the subsequent determinations and quantifications.

Chelex-purified DNA from New World Leishmanias L. (L.) amazonensis, L. (V.) guyanensis, L. (V.) panamensis, L. (V.) braziliensis were also obtained from the same Institution. These strains were isolated from clinical samples in Argentina and typed at the species level at the Institute of Biomedicine and molecular immunology, CNR (Palermo, Italy). The DNA concentration of the New World Leishmania species was also analyzed, and the following results were obtained.

**Figure 1. L. (L.) infantum kDNA minicircle DNA partial sequence (acc. n. Z35272) and primer localization.** The underlined bold sequences represent the MaryF–MaryR primers; the boxed sequences represent MLF–MLR primers.

doi:10.1371/journal.pone.0088845.g001

**Figure 2. Electrophoretic analysis of PCR products.** Agarose gel analysis of PCR products obtained with primers MaryF–MaryR (A) and MLF–MLR (B). 1,2: PCR products obtained with L. (L.) infantum MHOM/TN/80/IPT1 DNA as template; L: ladder; ntc: no template control.

doi:10.1371/journal.pone.0088845.g002
obtained: *L. (L.) amazonensis* 0.98 ng/µl, *L. (V.) guyanensis* 2.31 ng/µl, *L. (V.) panamensis* 1.79 ng/µl and *L. (V.) braziliensis* 1.32 ng/µl.

### Canine Samples

Canine peripheral blood and conjunctival swabs samples were provided by the veterinary clinic “S. Teresa” (Fano, Italy) as part of samples used for routine clinical tests. Sixty-two animals were selected and grouped on the basis of IFAT test results and clinical signs reported by veterinary practitioners (i.e. lymphadenopathy, alopecia, skin ulceration, weight loss, onychogryposis, ocular lesions, epistaxis, lameness). IFAT was performed on serum samples, obtained from both symptomatic and asymptomatic dogs, with an in-house assay validated and provided by IZS of Sicily.

The buffy-coat samples (100 to 320 µl) were obtained after centrifugation of 1 ml peripheral blood at 1500 rpm for 10 minutes. The DNA was extracted from these samples using the DNeasy Blood & Tissue kit (Qiagen) following the manufacturer’s protocol with some slight modifications. In particular, the incubation time with proteinase K was prolonged to 2 h, and the elution was repeated twice with the same 200 µl elution buffer. Conjunctival swabs were collected from the right and left conjunctivae using sterile cotton swabs. The swabs were transferred into 1.5 ml sterile tubes, immersed in 200 µl lysis buffer (10 mM Tris-HCl pH 8.3, 50 mM KCl, 0.5% Nonidet P40, 0.5% Tween 20, 0.1 mg/ml proteinase K), and incubated 2 h at 56°C. After swabs elimination, the samples were incubated for 10 min at 95°C and centrifuged at 14,000 rpm for 10 min. Supernatants were used as template in PCR reactions.

### PCR Assays

The primers used to amplify a 140 bp conserved region of the *Leishmania* kDNA minicircle were from Mary et al. [15] (defined in this paper as MaryF and MaryR). Two new primers (forward MLF: 5’-CGTTCTGCAAAACCGAAA-3’; and reverse MLR: 5’-CGGCCCTATTTTACACCAACC-3’) were designed to target a 111 bp fragment of the same region of *L. (L.) infantum* kDNA minicircle (acc. n. Z35272) using the Primer Express software.
The positions of MLF-MLR primers as well as MaryF-MaryR primers along the kDNA minicircle sequence are depicted in Fig. 1.

Conventional PCR using both primer pairs was carried out in a 50 µl volume with 25–50 ng template DNA, containing 200 µM dNTPs, 2.5 mM MgCl₂, 200 nM of each primer and 1U Hot-Rescue DNA Polymerase (Diateva). The amplification was performed in a GeneAmp PCR System 2700 (Applied Biosystems). The thermal cycling profile was as follows: 94°C for 7 min, followed by 35 cycles at 94°C for 30 s, 60°C for 20 s and 72°C for 20 s, with a final extension at 72°C for 5 min. Each sample was amplified in duplicate. Amplified fragments were analyzed by electrophoresis in a 1.8% agarose gel containing Gel Red (1:10,000) (Sichim, Italy). The gels were visualized under UV light using a gel doc apparatus (Bio-Rad).

Two qPCR assays were named as qPCR1 and qPCR2 and were performed using MaryF-MaryR primers and MLF-MLR primers, respectively. Both qPCR were carried out in a 25 µl volume with 1 µl template DNA and 24 µl SYBR green PCR master mix (Diateva srl, Italy) containing 1U Taq Polymerase and 200 nM of each primer. The PCR reactions were performed in a Rotor-Gene 6000 instrument (Corbett life science, Australia). The amplification profile was: 94°C for 10 min, followed by 40 cycles at 94°C for 30 s, 60°C for 20 s and 72°C for 20 s. At the end of each run, a melting curve analysis was performed from 55°C to 95°C to monitor primer dimers or non-specific product formation. The reactions were performed in duplicate or triplicate.

A standard curve was established using Chelex-purified L. (L.) infantum DNA; 1 µl of serial dilutions, ranging from 100 to 0.001 parasites, was introduced into reaction tubes. The standard curve concentration was expressed as parasite/µl (par/µl).

In order to evaluate the potential interference of host DNA as background in the qPCR analysis, we spiked the qPCR reactions, containing L. (L.) infantum DNA from 100 to 0.001 parasites, with 100 ng or 30 ng of human or canine DNA, respectively. The amount of canine DNA approximately reflected the median amount of DNA from clinical samples used as templates. All quantification analyses were performed with the Rotor-Gene 6000 software. Primer sequence specificity was confirmed in silico by BLAST searches in the subset database order Kinetoplastida.

![Figure 4](https://example.com/figure4.png)  
**Figure 4. Calibration curves constructed with plasmid serial dilutions.** Standard curves were obtained from serial dilutions of plasmid 1 (A) and plasmid 3 (B) with primers MaryF-MaryR and MLF-MLR, respectively. Each point derived from duplicates of 3 independent experiments. doi:10.1371/journal.pone.0088845.g004
assay specificities were also tested with DNA purified from *Trypanosoma cruzi*, obtained from the Institute of Biomedicine and Molecular Immunology, CNR (Palermo, Italy). To exclude false-negative results due to low DNA extraction efficiency or the presence of PCR inhibitors, a random subset (approximately 24%) of canine DNA samples which resulted qPCR-negative were tested for the quantitative amplification of the beta-2-microglobulin (B2M) gene using primers B2Mcanis_F (5'-GTCCCAGATCCCACTCAAG-3') and B2Mcanis_R (5'-CTGGTGGA TGGAACCCTGAC-3') with qPCR conditions as reported above.

**High Resolution Melt (HRM) Analysis**

HRM curves acquisition was performed after PCR amplification on a Rotor-Gene 6000 instrument (Corbett life science, Australia). HRM range was set from 75°C to 92°C, with a slope of 0.1°C/s, and 2 s at each temperature. Each sample was run in duplicate or triplicate and gain was optimized before melt on all tubes. HRM curve analysis was performed with the derivative of the raw data, after smoothing, with the Rotor-Gene 6000 software.

To analyze intra-assay variation, the standard curve ranging from 100 to 0.01 *L. (L.) infantum* parasites, and spiked with 30 ng of canine DNA, was tested with 3 replicates within one run, and the coefficient of variation (CV) was calculated.

**Cloning and Sequencing**

The PCR product amplified with primers MaryF-MaryR from the *L. (L.) infantum* MHOM/TN/80/IPT1 strain was cloned in the plasmid pCR®2.1 using the TA cloning Kit (Qiagen) and *E. coli* Top10 F competent cells. The recombinant plasmids were purified from five colonies (1, 2, 3, 4, 17) using QIAprep mini kit (Qiagen). The plasmid concentration was estimated using a gel doc apparatus (Biorad) by 1.6% agarose gel electrophoresis and λDNA/HindIII marker (Thermo Scientific) as a reference. Plasmid copy number was calculated using the molar

| Species subgenus | Tm peak 1 (°C) | Tm peak 2 (°C) |
|------------------|----------------|----------------|
| *L. infantum* Leishmania | 83.20±0.47 | 84.32±0.34 |
| *L. amazonensis* Leishmania | 84.09±0.26 | |
| *L. guyanensis* Viannia | 83.21±0.27 | |
| *L. panamensis* Viannia | 83.07±0.09 | |
| *L. braziliensis* Viannia | 83.08±0.21 | |
| *L. infantum* Plasmid 3 Leishmania | 83.02±0.12 | |
| *L. infantum* Plasmid 17 Leishmania | 83.34±0.30 | |

Tm values are ± SD.
The PCR products obtained with MaryF-MaryR primers from canine clinical samples and New World Leishmanias were purified using the Minelute PCR purification kit (Qiagen) and directly sequenced using MaryF and MaryR primers.

All sequences were performed on a ABI PRISM 310 Genetic Analyzer (Applied Biosystems).

### Specificity and Sensitivity of PCR Assays

Initially, to test the primers performance on DNA from *L. (L.) infantum* MHOM/TN/80/IPT1, 2.3 ng of template DNA were amplified by conventional PCR either with MaryF-MaryR primers and MLF-MLR primers. The electrophoretic analysis of the PCR mixtures showed the amplicons at the expected size (140 bp and 111 bp, respectively) and the absence of non-specific products or primer dimers (Fig. 2).

Subsequently, qPCR conditions with SYBR green were optimized with MaryF-MaryR and MLF-MLR primers: the PCR products obtained with MaryF-MaryR primers from *L. (L.) infantum* MHOM/TN/80/IPT1 strain by qPCR. Two standard curves were constructed with serial dilutions of plasmid 1 (ranging from 3.36×10^6 to 3.36×10^3 copies/PCR tube) or plasmid 3 (ranging from 3.59×10^6 to 5.59×10^3 copies/PCR tube) for amplification with primers MaryF-MaryR, or MLF-MLR, respectively.

### Statistical Analysis

Statistical analysis to evaluate differences among Tm values was performed using a Mann-Whitney test on GraphPad InStat (GraphPad Software, San Diego, CA).

### Results

### Specificity and Sensitivity of PCR Assays

In order to exclude possible interference of background DNA derived from clinical specimens in qPCR assays, different amounts of *L. (L.) infantum* DNA (down to 1×10^{-3} parasites equivalent) were amplified in the presence of 100 ng of human DNA or 30 ng of canine DNA as background. Although the PCR efficiencies were affected by the presence of background DNA, 1×10^{-3} parasites were detected and the sensitivity of the assays remained unchanged (Fig. S2). The qPCR2 sensitivities for *L. (L.) amazonensis*, *L. (V.) guyanensis*, *L. (V.) panamensis*, *L. (V.) braziliensis* were 1.0×10^{-2}, 2.5×10^{-3}, 2.0×10^{-4}, 1.3×10^{-3} ng/PCR tube, respectively.

### kDNA Minicircle Quantification

kDNA minicircle quantification was first performed using MaryF-MaryR primers (qPCR1 assay). Serial dilutions of the PCR product cloned into a plasmid (plasmid 1), ranging from 3.36×10^6 to 3.36×10^3 copies, were used to construct the calibration curve. The kDNA minicircles were quantified in chelex-purified DNA equivalent to 10 and 1 par/μl. The quantification was performed in three independent experiments. The three standard curves were gathered, showing good correlation (Fig. 4A) and reproducible quantification results. We found 26,566±1,192 kDNA minicircles amplifiable by MaryF-MaryR primers in *L. (L.) infantum* MHOM/TN/80/IPT1.

The plasmid 1 was not amplifiable using MLF-MLR primers (data not shown). In fact, the cloned DNA sequence showed two mismatches with the MLF primer (see below). However, these primers successfully amplified a different cloned sequence (plasmid 3). Hence, serial dilutions of recombinant plasmid 3, ranging from 3.39×10^6 to 3.59×10^5 copies, were used in the construction of the calibration curve for kDNA minicircle quantification by MLF-MLR primers (Fig. 4B). Dilutions of 100 and 10 par/μl were tested in duplicate obtaining an average of 1,263±115 kDNA minicircles per parasite amplifiable by MLF-MLR primers. Since the MLF-MLR primers are nested to MaryF-MaryR primers, the cloned DNA sequence showed two mismatches with the MLF primer. Moreover, the cloned DNA sequence showed two mismatches with the MLF primer.

### Melting Analysis

Melting analysis of PCR products obtained with MaryF-MaryR primers (qPCR1) did not show significant Tm differences for the two subgenera *Leishmania* (Leishmania) (average Tm 87.62±0.18;
| Clinical status                  | Sample ID | IFAT titre | qPCR1 Parasite load (par/ml blood) | qPCR2 Parasite load (par/ml blood) | Tm HRM peak 1 | Tm HRM peak 2 |
|--------------------------------|-----------|------------|-----------------------------------|-----------------------------------|---------------|---------------|
| Diagnosed Leishmaniasis        | 1         | 1:80       | 0.35                              | 0.27                              | –             | 84.73 ± 0.07  |
|                                | 2         | n.a.       | 0.10                              | 0.14                              | 83.62 ± 0.14  | 84.54 ± 0.23  |
|                                | 3         | ≥1:160     | 1.72                              | 12.24                             | –             | 83.87 ± 0.05  |
|                                | 4         | ≥1:160     | 8.00                              | 2.40                              | –             | 83.95 ± 0.04  |
|                                | 5         | ≥1:160     | 20.58                             | 1.27                              | 83.82 ± 0.23  | 84.80 ± 0.10  |
|                                | 8         | ≥1:160     | 1.40                              | 5.00                              | 83.95 ± 0.25  | 84.68 ± 0.25  |
|                                | 9         | ≥1:160     | 3.18                              | 26.91                             | 84.07 ± 0.12  | 84.80 ± 0.04  |
|                                | 21        | ≥1:160     | 0.52                              | 19.88                             | –             | 84.23 ± 0.07  |
|                                | 22        | ≥1:160     | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 23        | ≥1:160     | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 24        | ≥1:160     | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 25        | ≥1:160     | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 28        | ≥1:160     | neg                               | neg                               | –             | –             |
|                                | 29        | ≥1:160     | 0.88                              | 4.94                              | –             | 84.21 ± 0.13  |
|                                | 30        | ≥1:160     | 1.66                              | 19.20                             | 84.22 *       | 85.40 ± 0.04  |
|                                | 31        | ≥1:160     | 0.25                              | 1.41                              | 84.68 ± 0.14  | 85.37 *       |
|                                | 32        | ≥1:160     | 0.56                              | 4.68                              | 84.1 ± 0.08   | 84.83 ± 0.08  |
| Asymptomatic Leishmaniasis     | 6         | neg        | 22.27                             | 10.40                             | 83.03 ± 0.07  | 83.94 ± 0.08  |
|                                | 7         | neg        | 4.26                              | 6.45                              | 83.71 ± 0.06  | 84.45 ± 0.11  |
|                                | 10        | neg        | neg                               | –                                 | –             | –             |
|                                | 11        | neg        | neg                               | –                                 | –             | –             |
|                                | 12        | neg        | neg                               | –                                 | –             | –             |
|                                | 13        | neg        | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 33        | neg        | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 49        | neg        | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 50        | neg        | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 51        | neg        | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 52        | neg        | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 53        | neg        | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 54        | neg        | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 55        | neg        | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 56        | neg        | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 57        | neg        | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 58        | neg        | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 59        | neg        | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 60        | neg        | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 61        | neg        | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 62        | neg        | neg                               | n.a.                              | n.a.          | n.a.          |
| Suspected Leishmaniasis        | 14        | 1:40       | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 15        | 1:40       | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 16        | 1:80       | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 17        | 1:80       | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 34        | 1:40       | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 35        | 1:80       | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 36        | 1:40       | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 37        | 1:40       | neg                               | n.a.                              | n.a.          | n.a.          |
|                                | 38        | 1:40       | neg                               | n.a.                              | n.a.          | n.a.          |
Table 3. Cont.

| Clinical status | Sample ID | IFAT titre | qPCR1 | qPCR2 |
|-----------------|-----------|------------|-------|-------|
|                 |           |            | Parasite load (par/ml blood) | Parasite load (par/ml blood) | Tm HRM peak 1 | Tm HRM peak 2 |
|                 |           |            | neg   | neg   | -     | -             |
|                 | 40        | 1:40       | neg   | n.a.  | n.a.  | n.a.          |
|                 | 41        | 1:40       | neg   | n.a.  | n.a.  | n.a.          |
| Monitored after therapy | 18 | ≥1:160 | neg | neg | - | - |
|                 | 19        | ≥1:160     | neg   | neg   | -     | -             |
|                 | 20        | ≥1:160     | neg   | neg   | -     | -             |
|                 | 26        | ≥1:160     | 0.29  | 26.21 | 83.30±0.71 | 84.23±0.81 |
|                 | 27        | ≥1:160     | 0.21  | neg   | -     | -             |
|                 | 44        | ≥1:160     | neg   | neg   | -     | -             |
|                 | 45        | 1:80       | neg   | n.a.  | n.a.  | n.a.          |
|                 | 46        | ≥1:160     | neg   | n.a.  | n.a.  | n.a.          |
|                 | 47        | ≥1:160     | neg   | n.a.  | n.a.  | n.a.          |
|                 | 48        | ≥1:160     | neg   | n.a.  | n.a.  | n.a.          |

*only one replicate showed the melting peak.

neg: negative.
n.a.: not available.

Figure 6. Sequence alignment of kDNA minicircle conserved region amplified with primers MaryF-MaryR.

Panel A: alignment of five clones derived from L. (L.) infantum MHOM/TN/80/IPT1 strain. Panel B: alignment of PCR products from canine clinical samples. Panel C: alignment of PCR products obtained from New World Leishmania species. The boxed sequence represents the MLF primer. Underlined sequences represent CSBs box.

doi:10.1371/journal.pone.0088845.g006
Genetic Variability of kDNA Minicircles

To investigate the genetic variability in the kDNA minicircle sequences amplified by qPCR1 assay, 5 cloned sequences obtained from L. (L.) infantum MHOM/TN/80/IPT1 were bidirectionally sequenced. Moreover, 10 amplicons obtained from canine clinical samples were directly sequenced. Comparing these nucleotide sequences by CLUSTALW2 [25], numerous polymorphic loci were highlighted both on plasmidic clones and on clinical samples (fig. 6A/B). Interestingly, we also found a single base polymorphism G/C in the conserved sequence block 1 (CSB-1).

Regarding the New World species, the sequences of Mary’s amplicons were similar to L. (L.) infantum (fig. 6C), suggesting that Mary’s primers amplify a subclass of minicircles conserved among different subgenera or species.

Discussion

A singular characteristic of the Kinetoplastida order is the mitochondrial DNA network organized in 20–50 maxicircles and 10,000–20,000 kDNA minicircles [21,26]. With respect to the Leishmania genus, about 10,000 kDNA minicircles are estimated per parasite [19]. The conserved region of these minicircles has been used as a diagnostic PCR target since the 1990s [27]. Several genomic targets, other than the kDNA minicircle conserved region, have allowed species or complex differentiation in qPCR [28–30]. However, these assays may be less sensitive due to the lack of multiple copies of target sequence per cell.

The primers designed by Mary et al [15] have been widely used for L. (L.) infantum detection with the Taqman probe [31,32]. We used these primers and a new primer pair (MLF-MLR) in a quantitative real-time PCR assay based on SYBR green chemistry. Good sensitivity, specificity and efficiency were obtained with both pairs of primers, although some inhibition was noted using an elevated amount (100 ng) of human DNA as background. Nevertheless, this inhibition did not affect the sensitivity of both assays.

These assays were used to make diagnoses in several canine blood samples, generally confirming the qualitative results obtained with IFAT. The discrepancies observed between IFAT and qPCR in samples from dogs diagnosed with Leishmaniaisusi (22, 23, 24, 25, 28) may be due to the low parasite content in blood compared to that which is found in bone marrow, lymphnodes or ocular conjunctiva [33]. In fact, a subsequent qPCR in conjunctival swabs from those dogs yielded positive results. On the contrary, the case of two samples that were qPCR positive and IFAT negative from asymptomatic dogs highlights the sensitivity of molecular methods, making this approach also useful for blood donor screening.

The discrepancies in quantification results between qPCR1 and qPCR2 may be explained by kDNA minicircle variability, in terms of number and sequence heterogeneity, in clinical samples. In fact, quantifications were performed using a standard curve obtained with DNA from the L. (L) infantum MHOM/TN/80/IPT1 strain.

Parasite quantification could be useful in follow-up, disease relapse or therapy monitoring. Parasite quantification by qPCR can be performed using standard curves obtained either with parasite serial dilutions or with dilutions of a cloned target sequence [34]. In this last case it is very important to know the amount of the PCR target per cell [35]. We attempted to quantify the amount of kDNA minicircles in L. (L) infantum MHOM/TN/80/IPT1 WHO international reference strain with MaryF-MaryR primers and MLF-MLR primers using a cloned sequence as reference standard, resulting in about 26,000 and 1,200 copies per cell, respectively. The value obtained with MaryF-MaryR primers is greater than the value usually reported in literature [19,34]. This may be due to the variability in kDNA minicircle number observed among different strains [15]. On the other hand, the value obtained with MLF-MLR primers represents a subclass of minicircles matching the primer sequences, as demonstrated by sequencing data. In fact, the heterogeneity of the kDNA minicircle conserved region was shown by sequencing five cloned sequences amplified with Mary’s primers (clones n. 1, 2, 3, 4, 17). The sequences were aligned, revealing several variations. Only clone n. 5 showed a perfect match with MLF-MLR primers, indicating that the kDNA minicircle sequence amplified by these primers was a subclass of the total kDNA minicircle population. This variability could make absolute quantification of Leishmania parasites in clinical samples difficult to achieve; however, the qPCR assays could still be useful for monitoring the relative changes of parasite load.
loads during disease and/or therapy in clinical specimens from single patients.

The GC content in the Mary’s amplicons varied between 53.2% (clone n. 5) and 48.9% (clone n. 17), accounting for the two melting peaks observed in HRM analysis. Direct sequencing of qPCR1 amplicons from clinical samples confirmed the heterogeneity of these samples (Fig. 6B). Due to the observed variability, SYBR green-based assays seem to be preferable to probe-based products from clinical samples. Due to the observed variability, yet-to-be-described polymorphic site (G/C) in the conserved block (CSB-1), which was confirmed with direct sequencing of PCR products from clinical samples. Due to the observed variability, SYBR green-based assays seem to be preferable to probe-based assays, unless the probe is designed on the 27 conserved

These PCR assays were also used to test New World Leishmania species: L. (L.) amazonensis, L. (V.) guyanensis, L. (V.) panamensis and L. (V.) braziliensis. As represented in Fig. S2, primers MaryF-MaryR and MLF-MLR amplified all these New World species. However, a BLAST search highlighted the lack of sequence homology for MaryF-MaryR primers in L. (V.) guyanensis, L. (V.) panamensis and L. (V.) braziliensis kDNA minicircle sequences, and 4–7 mismatches in L. (L.) amazonensis kDNA minicircle sequences. In addition, MLF-MLR primers showed from 1 to 6 mismatches with these species’ sequences in Genbank database. Nevertheless, the kDNA minicircle sequences belonging to these species were also amplifiable under very stringent conditions (annealing temperature up to 65°C), indicating the presence of a subpopulation of minicircles with sequences matching the primers used. The fact that Mary’s primers can amplify New World species has recently been confirmed [36]. Taken together, these data suggest that Mary’s primers amplify a subclass of minicircles conserved among different subgenera or species. However, this does not explain the differences in Tm observed with MLF-MLR primers since the target of these primers belongs to a different subclass of minicircles.

When New World species DNA was used as a template, the qPCR2 assay resulted in lower Ct values than those found with the qPCR1 assay. Hence, it could be hypothesized that these New World species have more kDNA minicircles amplifiable (perfectly matching) by MLF-MLR primers respect to MaryF-MaryR primers.

The early characterization of the infecting parasite is important for appropriate treatment and evolution of the disease [9]. The ability to discriminate between the subgenera Leishmania (Leishmania) and Leishmania (Viannia) using real-time PCR and melt analysis targeting kinetoplast DNA has already been demonstrated in Brazilian Leishmania strains [24]. Here we confirmed that it is possible to discriminate between Leishmania (Leishmania) and Leishmania (Viannia) subgenera using MLF-MLR primers. The assays were performed on the L. (L.) infantum WHO reference strain and L. (L.) amazonensis, L. (V.) guyanensis, L. (V.) panamensis, L. (V.) braziliensis isolates (Fig. 5B).

Saturating fluorescent dyes such as LC Green, SYTO9 or Eva Green were generally considered necessary for HRM analysis [37]. However, also SYBR Green has proven to be a very successful dye for HRM analysis using the Rotor-Gene 6000 [38,39], probably due to the technical features of this instrument (i.e. high thermal precision, short optical path, multiple readings for each thermal point). Therefore, performing HRM analysis with SYBR green, we were able to further confirm the Tm differences and to discriminate, in the subgenus Leishmania (Leishmania), between L. (L.) infantum WHO reference strain and L. (L.) amazonensis (Fig. 5D). These results were also confirmed in 15 canine clinical samples from Central Italy: although clinical samples showed a greater variability in Tm, it was always possible to confirm the presence of Leishmania (Leishmania) DNA or to exclude the presence of Leishmania (Viannia) DNA. Moreover, in 10 of 15 samples, the HRM profile typical of the L. (L.) infantum WHO reference strain was also confirmed. The fact that five clinical samples did not show the first peak may be due to kDNA minicircle variability in the parasite. Samples that amplify late (Ct>30) or fail to reach a plateau in the PCR phase can result in inconclusive or low-resolution HRM data [40]. In our experience, reproducible Tm profiles were obtained when amplicons Ct values were approximately from 20 to 30. Out of this range, it should be difficult to compare Tm profiles (Table 2) and this could be a limit of the method when clinical samples with low parasite load are analyzed.

The fact that clinical sample DNA was in low-salt buffer and DNA from L. (L.) infantum MHOM/TN/80/IPT1 (used as positive control in all qPCR and HRM analyses) was Chelex-purified did not affect the analyses since chelex-purified DNA was diluted at least 1:10,000 prior to be used as template and proved not to induce PCR inhibition.

In conclusion, the new SYBR green-based assay developed using MLF-MLR primers was shown to reliably detect L. (L.) infantum in canine clinical samples. Moreover, the kDNA minicircle constant region in the L. (L.) infantum WHO international reference strain was quantified and several polymorphic sites were highlighted. The qPCR2 followed by HRM analysis has shown to be able to discriminate between subgenera Leishmania (Leishmania) and Leishmania (Viannia), confirming the results previously obtained in Brazilian strains, and to differentiate the L. (L.) infantum WHO reference strain from L. (L.) amazonensis.

Supporting Information

Figure S1 Melting analysis of PCR products. Melting temperature analysis of amplicons generated with primers MaryF-MaryR (A) and MLF-MLR (B) were equivalent to 100, 0.1, 0.01 and 0.001 parasites/tube. (PPT)

Figure S2 Conventional PCR under stringent conditions. The PCR was conducted under stringent conditions (annealing temperature 65°C) with primers MaryF-MaryR (A) and MLF-MLR (B). 1: L. (L.) infantum (2.3×10^4 ng DNA/tube) (positive control); 2: L. (L.) amazonensis (1 ng DNA/tube); 3: L. (V.) guyanensis (2.3 ng DNA/tube); 4: L. (V.) panamensis (1.8 ng DNA/tube); 5: L. (V.) braziliensis (1.5 ng DNA/tube). All samples were tested in duplicate. A 100 bp-DNA ladder and a marker 9 (Fermentas) were used as reference in panel A and B, respectively. (PPT)

Figure S3 Standard curves with human DNA as background. Standard curves were obtained from serial dilutions of L. (L.) infantum MHOM/TN/80/IPT1 DNA with primers MaryF-MaryR (A) and MLF-MLR (B) in the presence of 100 ng of human DNA per PCR tube. L. (L.) infantum DNA scalar dilutions were equivalent to 100, 0.1, 0.01 and 0.001 parasites/tube. (PPT)

Figure S4 Standard curves with canine DNA as background. Standard curves were obtained from serial dilutions of L. (L.) infantum MHOM/TN/80/IPT1 DNA with primers MaryF-MaryR (A) and MLF-MLR (B) in the presence of 30 ng of canine DNA per PCR tube. L. (L.) infantum DNA scalar dilutions were equivalent to 100, 10, 1, 0.1, 0.01 and 0.001 parasites/tube. (PPT)
Figure S5 Representative HRM profiles of amplicons obtained with MLF-MLR primers (qPCR2) in clinical samples. All samples are shown in duplicates. The melting profile of 2 L. (L.) infantum MHOM/TN/88/IPT1 was always included as reference. The samples 3 and 4 show a single peak, corresponding to peak 2 of L. (L.) infantum (A). The samples 2, 6, 7, 8 show two peaks corresponding to peak 1 and 2 of L. (L.) infantum (B, C, D). Tm values are indicated in Table 3.

Acknowledgments

We would like to thank Dr. Fabrizio Vitale, Dr. Tiziana Lupo, Dr. Stefano Reale from EFS Palermo and Dr. Mirella Giaccio from CNR Palermo for providing Leishmania strains and isolates. We also wish to thank the Veterinary Clinic “S. Teresa”, Fano (PU), Italy, for providing canine clinical samples; Dr. Mirco Fanelli, Dr. Stefano Amatori and Dr. Elena Bertozzini from the Biotechnology section of University of Urbino for technical assistance.

Author Contributions

Conceived and designed the experiments: MC LG. Performed the experiments: MC. Analyzed the data: MC LG MM. Contributed reagents/materials/analysis tools: AM MM. Wrote the paper: MC LG.

References

1. Murray HW, Berman JD, Davies CR, Saravia NG (2005) Advances in leishmaniasis. Lancet 366: 1561–1577.
2. Alvar J, Velez ID, Bern C, Herrera M, Desjeux P, et al. (2012) Leishmaniasis worldwide and its economic impact. PLoS Med 9: e1001346.
3. Desjeux P (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27: 305–318.
4. Marty P, Le FY, Giordana L, Brugnett A (1992) Leishmanin reaction in the human population of a highly endemic focus of canine leishmaniasis in Alpes-Maritimes, France. Trans R Soc Trop Med Hyg 86: 249–250.
5. Semina-Santo Sj, el Ha, Ferreira E, Pires CA, Sousa C, et al. (1995) Ikaroa as a new focus for canine leishmaniasis in Portugal. Parasitol Res 81: 259–269.
6. Alvar J, Canavate C, Molina R, Moreno J, Nieto J (2004) Canine leishmaniasis. Adv Parasitol 57: 1–88.
7. Cabral M, O’Grady JE, Gomes S, Sousa JC, Thompson H, et al. (1998) The immunology of canine leishmaniasis: strong evidence for a developing disease spectrum from asymptomatic dogs. Vet Parasitol 76: 173–180.
8. Sideris V, Papadopoulou G, Dotulka E, Karagouni E (1999) Asymptomatic canine leishmaniasis in Greater Athens area, Greece. Eur J Epidemiol 15: 271–276.
9. Goto H, Lindsjo JA (2010) Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 8: 419–433.
10. Gradoni L, Gramiccia M (2000) Leishmaniasis. OIE manual of standards for diagnostic tests and vaccine, Office International des Epizooties, pp. 802–812.
11. Inesta L, Fernandez-Barredo S, Bulle B, Gomez MT, Piazzoli R, et al. (2002) Diagnostic techniques to detect cryptic leishmaniasis in dogs. Clin Diagn Lab Immunol 9: 1137–1141.
12. Gradoni L, Gramiccia M, Khoury C, Maroli M (2004) Guidelines for the control of the canine reservoir of zoonotic visceral leishmaniasis in Italy. Rappont ISTISAN 04/12. Istituto Superiore di Sanitá, Rome, Italy.
13. Sudarshan M, Weirather JL, Wilson ME, Sundar S (2011) Study of parasite dispersal and population structure in Leishmania infantum, Mem Inst Oswaldo Cruz 106: 1751–1755.
14. Manna L, Reale S, Vitale F, Picillo E, Pavone LM, et al. (2008) Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol. Vet J 177: 279–282.
15. Mary C, Faraut F, Lascombe L, Dumon H (2004) Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity. J Clin Microbiol 42: 5249–5253.
16. Lachaud L, Chartier E, Dubessy P, Reynes J, Lamothe J, et al. (2002) Comparison of various sample preparation methods for PCR diagnosis of visceral leishmaniasis using peripheral blood. J Clin Microbiol 39: 613–617.
17. Lachaud L, Marchegui-Hammami S, Chabbert E, Duretre J, Dedet JP, et al. (2001) Determination of Leishmania species and complexes by a real-time fluorescence resonance energy transfer-based real-time PCR assay. J Clin Microbiol 39: 1529–1535.
18. Tupperwar N, Vinceth V, Rathi S, Vaidya T (2008) Development of a real-time polymerase chain reaction assay for the quantification of Leishmania species and the monitoring of systemic distribution of the pathogen. Diagn Microbiol Infect Dis 61: 23–30.
19. Tsukayama P, Nunez JH, De Los SM, Soberon V, Lucas CM, et al. (2013) A FRET-based real-time PCR assay to identify the main causal agents of New World tegumentary leishmaniasis. PLoS Negl Trop Dis 7: e1956.
20. Aoun O, Mary C, Roqueplo C, Marie JL, Terrier O, et al. (2009) Canine leishmaniasis in south-east of France: screening of Leishmania infantum antibodies (western blotting, ELISA) and parasitaemia levels by PCR quantification. Vet Parasitol 166: 27–31.
21. Martin-Esquerre G, Fisa R, Riera C, Rocamarra V, Fernandez-Casado A, et al. (2009) Role of Leishmania spp. infection in non-diagnostic cutaneous granulomatous lesions: report of a series of patients from a Mediterranean area. Br J Dermatol 161: 320–325.
22. Gramiccia M, Di MT, Fiorentino E, Scaloni A, Bongiorno G, et al. (2010) Longitudinal study on the detection of canine Leishmania infections by congnocutaneous analysis and correlation with entomological parameters. Vet Parasitol 171: 223–228.
23. Quaresma PF, Murta SM, Ferreira EC, da Rocha-Lima AC, Xavier AA, et al. (2009) Molecular diagnosis of canine visceral leishmaniasis: identification of Leishmania species by PCR-RFLP and quantification of parasite DNA by real-time PCR. Acta Trop 111: 289–294.
24. Galuzzi L, Bertozzini E, Perna A, Perini F, Garce B, et al. (2010) Analysis of DNA-rRNA gene content in the Mediterranean dinoflagellate Alexandrium catenella and Alexandrium taylori: implications for the quantitative real-time PCR-based monitoring methods. J Appl Physiol 22: 1–9.
25. Cruz I, Millet A, Carrillo E, Chenk M, Salora P, et al. (2013) An approach for interlaboratory comparison of conventional and real-time PCR assays for diagnosis of human leishmaniasis. Exp Parasitol 134: 281–289.
26. Reed GH, Kent JO, Wittwer CT (2007) High-resolution DNA melting analysis for simple and efficient molecular diagnostics. Pharmacogenomics 8: 597–608.
27. Price EP, Smith H, Huygens F, Gilford PM (2007) High-resolution DNA melt curve analysis of the clustered, regularly interspaced short-palindromic-repeat locus of Campylobacter jejuni. Appl Environ Microbiol 73: 3431–3436.
28. Porporaert S, Fhussa A, Suanta S, Saetung R, Sanguansermsri T (2008) Detection of alpha-thalassemia-1 Southeast Asian type using real-time gap-PCR with SYBR GreenI and high resolution melting analysis. Eur J Haematol 80: 510–514.
29. White H, Potts G (2006) Mutation scanning by high resolution melt analysis. Evaluation of RotorGene 6000 (Corbett Life Science), HR1 1310 and 384 well LightScanner 1310 (Idaho Technology). Technology Assessment. National Genetics Reference Laboratory (Wessex), Salisbury, UK.